SCHEMBL4710700

SCHEMBL4710700

NC(=O)COCCN1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.42
CYP1A2 P05177 1/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TSHR P16473 1/20 0.40
PSMB1 P20618 1/20 0.40
PSMB5 P28074 1/20 0.40
PSMB2 P49721 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
TACR1 P25103 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4709553 0.98 L3MBTL1 (0.57) L3MBTL1SMN1; SMN2CYP1A2MAPK1ALDH1A1
SCHEMBL22266212 0.94 L3MBTL1 (0.53) L3MBTL1SMN1; SMN2CYP1A2MAPK1ALDH1A1
SCHEMBL22266180 0.91 L3MBTL1 (0.50) L3MBTL1SMN1; SMN2CYP1A2MAPK1ALDH1A1
SCHEMBL22266219 0.90 L3MBTL1 (0.49) L3MBTL1SMN1; SMN2CYP1A2MAPK1ALDH1A1
SCHEMBL22266186 0.88 HRH3 (0.50) L3MBTL1SMN1; SMN2CYP1A2MAPK1ALDH1A1
SCHEMBL4710666 0.83 KDM4E (0.53) L3MBTL1SMN1; SMN2CYP1A2MAPK1ALDH1A1
SCHEMBL7603566 0.83 MEN1 (0.44) SMN1; SMN2ALDH1A1MAPTKDM4EMEN1
SCHEMBL7604063 0.82 TACR1 (0.40) L3MBTL1MEN1KMT2ATACR1
Hydrochloric Acid SCHEMBL7948069 0.82 MEN1 (0.43) SMN1; SMN2ALDH1A1MAPTKDM4EMEN1
SCHEMBL22266250 0.80 MEN1 (0.48) SMN1; SMN2ALDH1A1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917015-A1 NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-07 EP claimed
WO-2007019884-A1 NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO claimed
US-20050256154-A1 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides LUK KIN-CHUN 2005-11-17 US claimed
EP-1917015-A1 NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-07 EP disclosed
WO-2007019884-A1 NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed
US-20050256154-A1 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides LUK KIN-CHUN 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256154-A1 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides FGFR3, FGFR4, FGFR1 L3MBTL1 3096/4885SMN1; SMN2 3141/4885CYP1A2 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.